Press release
June 26, 2014
Corindus Vascular Robotics Receives Frost & Sullivan 2014 North American New Product Innovation Award in Interventional Cardiology

CorPath is first and only FDA-cleared robotic system for percutaneous coronary intervention (PCI)

Waltham, MA, June 26, 2014Corindus Vascular Robotics, the leader in precision vascular robotics, has been named the recipient of the 2014 North American New Product Innovation Award in Interventional Cardiology. The award was established by growth partnership company Frost & Sullivan to recognize visionary innovation and product excellence. Corindus’s CorPath Vascular Robotic System is the first medical device to bring robotic precision and accuracy to coronary angioplasty procedures, which may improve clinical outcomes while increasing radiation protection for interventional cardiologists.

“To achieve excellence in new product innovation leadership is not an easy task, but the CorPath system addresses a critical concern of interventional cardiologists, and has the potential to improve outcomes and economics in coronary angioplasty,” noted Greg Caressi, senior vice president, Healthcare & Life Sciences, Frost & Sullivan. “Corindus’s receipt of this award signifies a great accomplishment.”

The CorPath System stood out from other products in the market with the following key differentiators:

  • Fulfilling Unmet Needs in Interventional Cardiology. The CorPath System provides tremendous benefits that decrease key career-limiting issues that physicians tend to face as a result of radiation exposure.
  • Optimized Design Considerations for Cath Lab Use. The CorPath System was designed to have the physician sitting in the Interventional Cockpit, removed from radiation, in a robotic control unit that sits beside the patient on the patient table bedrail.
  • Advancing Care and Safety. The CorPath System can safely navigate through the vascular anatomy to perform balloon stenting techniques.
  • Innovative CorPath One Stent Program. Corindus Vascular Robotics launched the “CorPath® One Stent Program” to highlight the precision and accuracy of the CorPath System by offering a $1,000 credit to hospitals that use two or more stents per lesion in coronary angioplasties performed with CorPath.
  • Future Promise. The CorPath System is believed to have a future in emerging interventional techniques and could be leveraged for procedures in other related fields.

Corindus CEO David Handler said, “We are committed to pioneering a positive change in the delivery of healthcare and making a significant difference for patients, physicians and hospitals.

Frost & Sullivan has validated that the direction we’re moving in is the right one. On behalf of Corindus, we would like to express our thanks for this esteemed honor.”

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages more than 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window